Oncotarget

Vol 12, No 8

April 13, 2021

View Archive »

Order a Reprint

About The Cover

The cover for issue 8 of Oncotarget features Figure 6, "MDM2 can be targeted sarcoma cell lines independent of p53 status," by Desai, et al.

Table of Contents

News

Immunotherapy and fatigue: what we know and what we don’t know

Immunotherapy and fatigue: what we know and what we don’t know

https://doi.org/10.18632/oncotarget.27946

Muhammad Azeem Khan, Vaia Florou,  and Umang Swami
719-720
PDF  |  How to cite  |  Order a Reprint

Editorial

Drug exposure: still relevant after all these years

Drug exposure: still relevant after all these years

https://doi.org/10.18632/oncotarget.27899

David E. Gerber,  and William C. Putnam
721-722
PDF  |  How to cite  |  Order a Reprint

Up to your NEK2 in CIN

Up to your NEK2 in CIN

https://doi.org/10.18632/oncotarget.27918

Darcie D. Seachrist, Lindsey J. Anstine,  and Ruth A. Keri
723-725
PDF  |  How to cite  |  Order a Reprint

Research Papers

Analytic validation and clinical utilization of the comprehensive genomic profiling test, GEM ExTra®

Analytic validation and clinical utilization of the comprehensive genomic profiling test, GEM ExTra®

https://doi.org/10.18632/oncotarget.27945

Tracey White, Szabolcs Szelinger, Janine LoBello, Amy King, Jessica Aldrich, Nathan Garinger, Matthew Halbert, Ryan F. Richholt, Stephen D. Mastrian, Cody Babb, Audrey A. Ozols, Laurie J. Goodman, Gargi D. Basu,  and Thomas Royce
726-739
Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite  |  Press Release  |  Order a Reprint

Prognostic and therapeutic value of the Hippo pathway, RABL6A, and p53-MDM2 axes in sarcomas

Prognostic and therapeutic value of the Hippo pathway, RABL6A, and p53-MDM2 axes in sarcomas

https://doi.org/10.18632/oncotarget.27928

Chandni Desai, Jon Thomason, Jordan L. Kohlmeyer, Anna C. Reisetter, Parmanand Ahirwar, Khadijeh Jahanseir, Mariah Leidinger, Georgina Ofori-Amanfo, Karen Fritchie, Sadanandan E. Velu, Patrick Breheny, Dawn E. Quelle,  and Munir R. Tanas
740-755
Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite  |  Press Release  |  Podcast  |  Order a Reprint

Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib

Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib

https://doi.org/10.18632/oncotarget.27924

Yehia I. Mohamed, Sunyoung Lee, Lianchun Xiao, Manal M. Hassan, Aliya Qayyum, Rikita Hiatia, Roberto Carmagnani Pestana, Abedul Haque, Bhawana George, Asif Rashid, Dan G. Duda, Hesham Elghazaly, Robert A. Wolff, Jeffrey S. Morris, James Yao, Hesham M. Amin,  and Ahmed O. Kaseb
756-766
Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite  |  Press Release  |  Podcast  |  Order a Reprint

Controlling for cellular heterogeneity using single-cell deconvolution of gene expression reveals novel markers of colorectal tumors exhibiting microsatellite instability

Controlling for cellular heterogeneity using single-cell deconvolution of gene expression reveals novel markers of colorectal tumors exhibiting microsatellite instability

https://doi.org/10.18632/oncotarget.27935

Matthew A.M. Devall,  and Graham Casey
767-782
Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite  |  Press Release  |  Order a Reprint

Urine protein biomarkers of bladder cancer arising from 16-plex antibody-based screens

Urine protein biomarkers of bladder cancer arising from 16-plex antibody-based screens

https://doi.org/10.18632/oncotarget.27941

Kamala Vanarsa, Shereen Enan, Pooja Patel, Briony Strachan, Anto Sam Crosslee Louis Sam Titus, Aphrihl Dennis, Yair Lotan,  and Chandra Mohan
783-790
Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite  |  Press Release  |  Order a Reprint

The acylfulvene alkylating agent, LP-184, retains nanomolar potency in non-small cell lung cancer carrying otherwise therapy-refractory mutations

The acylfulvene alkylating agent, LP-184, retains nanomolar potency in non-small cell lung cancer carrying otherwise therapy-refractory mutations

https://doi.org/10.18632/oncotarget.27943

Aditya Kulkarni, Joseph Ryan McDermott, Umesh Kathad, Rama Modali, Jean-Philippe Richard, Panna Sharma,  and Kishor Bhatia
791-806
Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite  |  Press Release  |  Order a Reprint

Loss of CPAP causes sustained EGFR signaling and epithelial-mesenchymal transition in oral cancer

Loss of CPAP causes sustained EGFR signaling and epithelial-mesenchymal transition in oral cancer

https://doi.org/10.18632/oncotarget.27932

Radhika R. Gudi, Harinarayanan Janakiraman, Philip H. Howe, Viswanathan Palanisamy,  and Chenthamarakshan Vasu
807-822
Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite  |  Press Release  |  Order a Reprint

Carcinoma cells that have undergone an epithelial-mesenchymal transition differentiate into endothelial cells and contribute to tumor growth

Carcinoma cells that have undergone an epithelial-mesenchymal transition differentiate into endothelial cells and contribute to tumor growth

https://doi.org/10.18632/oncotarget.27940

Nathalie Sphyris, Cody King, Jonathan Hoar, Steven J. Werden, Geraldine V. Vijay, Naoyuki Miura, Akhilesh Gaharwar,  and Tapasree Roy Sarkar
823-844
Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite  |  Press Release  |  Order a Reprint

Predicting clinical outcomes using cancer progression associated signatures

Predicting clinical outcomes using cancer progression associated signatures

https://doi.org/10.18632/oncotarget.27934

Jared Mamrot, Nathan E. Hall,  and Robyn A. Lindley
845-858
Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite  |  Press Release  |  Order a Reprint

High in vitro and in vivo synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC

High in vitro and in vivo synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC

https://doi.org/10.18632/oncotarget.27930

Elodie Montaudon, Rania El Botty, Sophie Vacher, Olivier Déas, Adnan Naguez, Sophie Chateau-Joubert, Damien Treguer, Ludmilla de Plater, Leïla Zemoura, Fariba Némati, André Nicolas, Alain Chapelier, Alain Livartowski, Stefano Cairo, Catherine Daniel, Marie Brevet, Elisabetta Marangoni, Didier Meseure, Sergio Roman-Roman, Ivan Bieche, Nicolas Girard,  and Didier Decaudin
859-872
Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite  |  Press Release  |  Order a Reprint


Copyright © 2021 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC